Trial Profile

A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patient with Platinum Resistant/Refractory Advanced Ovarian Cancers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Seribantumab (Primary) ; Paclitaxel
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Sponsors Merrimack Pharmaceuticals

Most Recent Events

20 Dec 2016 Results published in the Journal of Clinical Oncology
18 May 2016 Results from this and 2 other trials were presented at the AACR Precision Medicine Series, according to a Merrimack Pharmaceuticals media release.
30 Sep 2014 According to a Merrimack Pharmaceuticals media release, biomarker data was presented at the European Society of Medical Oncology (ESMO) 2014 Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com